Middle-term use of Cinacalcet in paediatric dialysis patients

Pediatric Nephrology

Volumn 25, Issue 1, 2010, Pages 143-148

  Platt, Caroline ^a   Inward, Carol ^a   McGraw, Mary ^a   Dudley, Jan ^a   Tizard, Jane ^a   Burren, Christine ^a   Saleem, Moin A ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Calcimimetic; Calcium; End stage renal failure; Metabolic bone disease; Paediatric; Parathyroid hormone; Phosphate

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE;

ADOLESCENT; ARTICLE; CALCIUM BLOOD LEVEL; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFANT; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFANT; KIDNEY FAILURE, CHRONIC; MALE; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 76749118843     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1294-7     Document Type: Article

References (30)

1. Peritoneal/heamodialysis clinical practice guidelines for children and adolescents (2007) Module 3. www.bapn.org. Treatment of adults and children with renal failure 3rd edition (2002) www.renal.org/guidelines (UK Renal Association)
2. National Kidney Foundation 2005 K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease Am J Kidney Dis 46 Suppl 1 S1 S121
3. IB Salusky BD Kuizon TR Belin JA Ramirez B Gales GV Segre WG Goodman 1998 Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration Kidney Int 54 907 914 10.1046/j.1523-1755.1998.00045.x 1:CAS:528:DyaK1cXlvVCmsLc%3D 9734615 (Pubitemid 28397408)
4. BD Kuizon WG Goodman H Jüppner I Boechat P Nelson B Gales IB Salusky 1998 Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD Kidney Int 53 205 211 10.1046/j.1523-1755.1998.00724.x 1:CAS:528:DyaK1cXnsFCiuw%3D%3D 9453020 (Pubitemid 28066923)
5. WG Goodman JA Ramirez TR Belin Y Chon B Gales GV Segre IB Salusky 1994 Development of adynamic bone disease in patients with secondary hyperparathyroidism after intermittent calcitriol therapy Kidney Int 46 1160 1166 10.1038/ki.1994.380 1:STN:280:DyaK2M7msFOnsg%3D%3D 7861712
6. S Waller S Ledermann R Trompeter W Van't Hoff D Ridout L Rees 2003 Catch-up growth with normal parathyroid hormone levels in chronic renal failure Pediatr Nephrol 18 1236 1241 10.1007/s00467-003-1284-0 14586680 (Pubitemid 37527097)
7. IB Salusky WG Goodman 2001 Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12 1978 1985 1:STN:280:DC%2BD3MvnsFeqsA%3D%3D 11518793
8. A Lefebvre MC de Vernejoul J Gueris B Goldfarb AM Graulet C Morieux 1989 Optimal correction of acidosis changes progression of dialysis osteodystrophy Kidney Int 36 1112 1118 10.1038/ki.1989.309 1:STN:280:DyaK3c%2Fps1yjsA%3D%3D 2557481
9. V Tasic 2005 Management of renal osteodystrophy in children Turk J Pediatr 47 Suppl 13 18 15884662
10. GA Block TE Hulbert-Shearon NW Levin FK Port 1998 Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic haemodialysis patients: a national study Am J Kidney Dis 31 607 617 10.1053/ajkd.1998.v31.pm9531176 1:STN:280:DyaK1c7ovFKlsw%3D%3D 9531176
11. D Goldsmith E Ritz A Covic 2004 Vascular calcification: a stiff challenge for the nephrologist: does preventing bon disease cause arterial disease? Kidney Int 66 1315 1333 10.1111/j.1523-1755.2004.00895.x 15458425 (Pubitemid 39298364)
12. WG Goodman J Goldin BD Kuizon C Yoon B Gales D Sider Y Wang J Chung A Emerick L Greaser RM Elashoff IB Salusky 2000 Coronary-artery calcification in young adults with end stage renal disease who are undergoing dialysis N Engl J Med 342 1478 1483 10.1056/NEJM200005183422003 1:STN:280:DC%2BD3c3ls1OjtA%3D%3D 10816185 (Pubitemid 30318271)
13. PC D'Haese GB Spasovski A Sikole A Hutchinson TJ Freemont S Sulkova C Swanepoel S Pejanovic L Djukanovic A Balducci G Coen W Sulowicz A Ferreira A Torres S Curic M Popovic N Dimkovic ME De Broe 2003 A multicenter study on the effects of lanthanum carbonate (Forsenol) and calcium carbonate on renal bone disease in dialysis patients Kidney Int 85 Suppl S73 S78 10.1046/j.1523-1755.63. s85.18.x
14. G Klaus A Watson A Edefonti M Fischbach K Ronnholm F Schaefer E Simkova CJ Stefanidis J Vande Walle C Schroder A Zurowska M Ekim 2006 Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines Pediatr Nephrol 21 151 159 10.1007/s00467-005-2082-7 1:STN:280:DC%2BD28%2FivVWisw%3D%3D 16247644 (Pubitemid 43115864)
15. EM Brown M Pollak D Riccardi SC Hebert 1994 Cloning and characterisation of an extracellular Ca2+ sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism Nephrol Dial Transplant 9 1703 1706 1:STN:280:DyaK2M3itlGiug%3D%3D 7708247
16. YC Li M Amling AE Pirro M Priemel J Meuse R Baron G Delling MB Demay 1998 Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice Endocrinology 139 4391 4396 10.1210/en.139.10.4391 1:CAS:528:DyaK1cXmsVGms7Y%3D 9751523
17. DK Panda D Miao I Bolivar J Li R Huo GN Hendy D Goltzman 2004 Inactivation of the 25-hydroxyvitamin D 1 alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis J Biol Chem 279 16754 16766 10.1074/jbc.M310271200 1:CAS:528:DC%2BD2cXivF2qu7k%3D 14739296 (Pubitemid 38509378)
18. S Sajid-Crockett FR Singer JM Hershman 2008 Cinacalcet for the treatment of primary hyperparathyroidism Metabolism 57 517 521 10.1016/j.metabol.2007.11. 014 1:CAS:528:DC%2BD1cXjtVens7s%3D 18328354 (Pubitemid 351317967)
19. GA Block KJ Martin AL de Francisco SA Turner MM Avram MG Suranyi G Hercz J Cunningham AK Abu-Alfa P Messa DM Coyne F Locatelli RM Cohen P Evenepoel SM Moe A Fournier J Braun LC McCary VJ Zani KA Olson TB Drueke WG Goodman 2004 The calcimimetic Cinacalcet (AMG 073) for the treatment of secondary hyperparathyroidism in haemodialysis patients N Engl J Med 350 1516 1525 10.1056/NEJMoa031633 1:CAS:528:DC%2BD2cXjtVeqtLY%3D 15071126 (Pubitemid 38477776)
20. A Francisco 2008 New strategies for the treatment of hyperparathyroidism incorporating calcimimetics Expert Opin Pharmacother 9 795 811 10.1517/14656566.9.5.795 18345956 (Pubitemid 351575060)
21. SM Moe GM Chertow JW Coburn LD Quarles WG Goodman GA Block TB Drueke J Cunningham DJ Sherrard LC McCary KA Olsen SA Turner KJ Martin 2005 Achieving K/DOQI bone metabolism and disease treatment goals with Cinacalcet HCL Kidney Int 67 760 771 10.1111/j.1523-1755.2005.67139.x 1:CAS:528:DC%2BD2MXhslSksLo%3D 15673327 (Pubitemid 40139871)
22. J Cunningham M Danese K Olson P Klassen GM Chertow 2005 Effects of the calcimimetic Cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 1793 1800 10.1111/j.1523-1755.2005.00596.x 1:CAS:528:DC%2BD2MXhtFequ7vI 16164656 (Pubitemid 43169924)
23. National Institute for Health and Clinical Excellence (2007) Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Available at www.nice.org.uk
24. JS Lindberg B Culleton G Wong MF Borah RV Clark WB Shapiro SD Roger FE Husserl PS Klassen MD Guo MB Albizem JW Coburn 2005 Cinacalcet HCL, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in haemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800 807 10.1681/ASN.2004060512 1:CAS:528: DC%2BD2MXis12nsr4%3D 15689407 (Pubitemid 41725117)
25. DM Silverstein KK Kher A Moudgil M Khurana J Wilcox K Moylan 2007 Cinacalcet is efficacious in paediatric dialysis patients Pediatr Nephrol 23 1817 1822 10.1007/s00467-007-0742-5
26. J Muscheites M Wigger E Drueckler D-C Fischer G Kundt D Haffner 2008 Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease Pediatr Nephrol 23 1823 1829 10.1007/s00467-008-0810-5 18504621
27. S Wu T Palese OP Mishra M Delivoria-Papadopoulos F De Luca 2004 Effects of Ca2+ sensing receptor activation in the growth plate FASEB J 18 143 145 1:CAS:528:DC%2BD2cXlvFOksQ%3D%3D 14597561
28. K Nakagawa EC Pérez J Oh F Santos A Geldyyev ML Gross F Schaefer CP Schmitt 2008 Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia Nephrol Dial Transplant 23 2761 2767 10.1093/ndt/gfn143 1:CAS:528:DC%2BD1cXhtF2qtLvM 18408076
29. WG Goodman 2003 Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials Pediatr Nephrol 18 1206 1210 10.1007/s00467-003-1290-2 14586685 (Pubitemid 37527091)
30. JR Sterrett J Strom H-K Stummvol U Bahner A Disney SD Soroka C Corpier JA Arruda LE Schwanauer PS Klassen KA Olson GA Block 2007 Cinacalcet HCL (Sensipar/Mimpara) is an effective chronic therapy for haemodialysis patients with secondary hyperparathyroidism Clin Nephrol 68 10 17 1:STN:280: DC%2BD2svos12qtg%3D%3D 17703830